Pharma Industry Encouraged to Adopt Mobile ePRO for Clinical Trials Efficiency
Exco InTouch, the leading provider of patient engagement and data capture solutions for clinical research and healthcare providers, is championing the industry to adopt mobile electronic Patient Reported Outcomes (ePRO) and other electronic Clinical Outcomes Assessments (eCOA) measures to ensure greater clinical trial success. Currently, over 80% of clinical trials experience delays and mobile ePRO can help mitigate these risks by increasing trial efficiency and patient adherence.
Responding to this issue, Exco InTouch will deliver insights into the application of mobile solutions across the clinical research industry, at this year’s 50th annual DIA meeting, taking place 15–19 June in San Diego.
Showcasing their position as the leader in the application of mobile in ePRO, the company will host on-site demonstrations and a series of 5 presentations, featuring industry-leading content from Tim Davis, CEO, Exco InTouch and Judith Teall, Director of Clinical Excellence. For those looking to learn more about the high value that mobile technology can offer to clinical trials, presentations will include ‘Electronic Clinical Outcome Assessments: Coming to a Device Near You!’ and ‘The Use of Mobile Technology to Place Patients at the Center of Clinical Trials’.
Exco InTouch, which will be exhibiting at booth 2116, will also demonstrate its approach to BYOD (bring your own device) and, more broadly to data capture and patient engagement services across clinical research programs. By enhancing clinical outcomes through improved patient compliance and data capture, their solutions will enhance trial efficiencies, ultimately speeding up potential times to market.
Tim Davis, CEO and co-founder of Exco InTouch commented: “Our presence at the DIA annual meeting will enable us to showcase our strengths as the industry leaders of mobile technology applications within clinical trials and the ease in which our services successfully captures ePRO. We are very much aware of the importance of making the clinical trial process simple for patients, and our technology, which enables a BYOD approach where appropriate, helps further increase patient engagement.”
He continued: “The global pharma industry is increasingly looking at ways to ensure its trials are run on time and with greater adherence. I would encourage everyone who wants to learn more about the benefits of our approach and the instruments and technologies that we have to offer, to visit our booth at DIA (2116) where we would be delighted to demonstrate our services first hand."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance